Switch theme
Sign up to access all valuation multiples
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
2009
17
LTM Revenue $7.0M
Last FY EBITDA -$11.8M
$29.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NeuroOne Medical has a last 12-month revenue (LTM) of $7.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, NeuroOne Medical achieved revenue of $3.5M and an EBITDA of -$11.8M.
NeuroOne Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NeuroOne Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.0M | XXX | $3.5M | XXX | XXX | XXX |
| Gross Profit | $7.0M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 31% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$11.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -343% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$11.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -344% | XXX | XXX | XXX |
| Net Profit | -$7.6M | XXX | -$12.3M | XXX | XXX | XXX |
| Net Margin | -109% | XXX | -357% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, NeuroOne Medical's stock price is $1.
NeuroOne Medical has current market cap of $30.4M, and EV of $29.4M.
See NeuroOne Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.4M | $30.4M | XXX | XXX | XXX | XXX | $-0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, NeuroOne Medical has market cap of $30.4M and EV of $29.4M.
NeuroOne Medical's trades at 6.2x EV/Revenue multiple, and -2.5x EV/EBITDA.
Equity research analysts estimate NeuroOne Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeuroOne Medical has a P/E ratio of -4.0x.
See valuation multiples for NeuroOne Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $30.4M | XXX | $30.4M | XXX | XXX | XXX |
| EV (current) | $29.4M | XXX | $29.4M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -2.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.0x | XXX | -2.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeuroOne Medical's last 12 month revenue growth is 60%
NeuroOne Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
NeuroOne Medical's rule of 40 is -446% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NeuroOne Medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NeuroOne Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 60% | XXX | 69% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -446% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 147% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 376% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeuroOne Medical acquired XXX companies to date.
Last acquisition by NeuroOne Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . NeuroOne Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NeuroOne Medical founded? | NeuroOne Medical was founded in 2009. |
| Where is NeuroOne Medical headquartered? | NeuroOne Medical is headquartered in United States of America. |
| How many employees does NeuroOne Medical have? | As of today, NeuroOne Medical has 17 employees. |
| Who is the CEO of NeuroOne Medical? | NeuroOne Medical's CEO is Mr. David A. Rosa. |
| Is NeuroOne Medical publicy listed? | Yes, NeuroOne Medical is a public company listed on NAS. |
| What is the stock symbol of NeuroOne Medical? | NeuroOne Medical trades under NMTC ticker. |
| When did NeuroOne Medical go public? | NeuroOne Medical went public in 2012. |
| Who are competitors of NeuroOne Medical? | Similar companies to NeuroOne Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of NeuroOne Medical? | NeuroOne Medical's current market cap is $30.4M |
| What is the current revenue of NeuroOne Medical? | NeuroOne Medical's last 12 months revenue is $7.0M. |
| What is the current revenue growth of NeuroOne Medical? | NeuroOne Medical revenue growth (NTM/LTM) is 60%. |
| What is the current EV/Revenue multiple of NeuroOne Medical? | Current revenue multiple of NeuroOne Medical is 4.2x. |
| Is NeuroOne Medical profitable? | Yes, NeuroOne Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
